EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium

Christine Worthington, Maria Raitses-Gurevich, Giulio Innamorati, Phil A Hart, Thomas M Wilkie, Noam Tau, Dana Brin, Doron Yablecovitch, Ido Laish, Dove Keith, Kurt Giles, Jennifer B Permuth iD und 6 weitere

International Journal of Cancer · 15.10.2026 · 159 (8) · 1873-1883

DOI: 10.1002/ijc.70592 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 15.06.2026. Verfasst von Christine Worthington und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Early Detection of Cancer, Biomarkers, Tumor, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late‐stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high‐grade precursors before clinical symptoms arise in patients at elevated risk of PDAC development. Classical imaging‐based surveillance strategies, aligned with current guidelines, form the foundation of screening high‐risk individuals, while organ‐specific fluid analyses—such as cyst fluid and pancreatic juice—offer promising complementary tools with enhanced specificity. Recent advances in radiomics, liquid biopsy, microbiome, and multi‐omics profiling are expanding the frontier of early detection. Despite advances, significant challenges persist. Precursor lesions are difficult to non‐invasively diagnose; are not radiologically or endosonographically visible, or cannot be definitively graded prior to resection. Though biomarkers show promise for early detection, they present unique challenges: early‐stage neoplasias release low levels of many biomarkers and thresholds for these biomarkers that define malignant transformation—and thus guide surgical intervention—remain poorly established. Multi‐institutional initiatives like the Pancreatic Cancer Early Detection consortium (PRECEDE) are critical to bridging discovery and clinical translation. Our international cohort study of high‐risk individuals was designed to discover and validate diagnostic biomarkers according to the PROBE study design. Continued collaboration, technological integration, and patient‐centered approaches are essential to transform early detection research into tangible survival benefits for those at risk of PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsEarly Detection of CancerBiomarkers, TumorCarcinoma, Pancreatic DuctalHumansLiquid Biopsy

Stichwörter der Autor:innen

biomarkersearly detectionimagingliquid biopsypancreatic cancerscreening

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • The Jusidman Cancer Center, Chaim Sheba Medical Center, Tel HaShomer Hospital, Ramat Gan, Israel.
  • Laboratory of Translational Surgery, Department of Surgery, Dentistry, Maternity and Infant, University of Verona, Verona, Italy.
  • Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Pharmacology Department, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Diagnostic Imaging, Chaim Sheba Medical Center, Tel HaShomer Hospital, Tel Aviv University, Ramat Gan, Israel.

ORCID-Profile: Jennifer B Permuth, Julie Earl

Zitieren

APA

Worthington, C., Raitses-Gurevich, M., Innamorati, G., Hart, P. A., Wilkie, T. M., Tau, N., Brin, D., Yablecovitch, D., Laish, I., Keith, D., Giles, K., Permuth, J. B., Simeone, D. M., Zogopoulos, G., Brand, R. E., Graff, J. J., Earl, J., & PRECEDE Consortium (2026). Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium. International Journal of Cancer, 159(8), 1873-1883. https://doi.org/10.1002/ijc.70592

Vancouver

Worthington C, Raitses-Gurevich M, Innamorati G, Hart PA, Wilkie TM, Tau N, et al. Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium. International Journal of Cancer. 2026;159(8):1873-1883. doi:10.1002/ijc.70592

BibTeX
@article{Worthington2026,
  author = {Worthington, Christine and Raitses-Gurevich, Maria and Innamorati, Giulio and Hart, Phil A and Wilkie, Thomas M and Tau, Noam and Brin, Dana and Yablecovitch, Doron and Laish, Ido and Keith, Dove and Giles, Kurt and Permuth, Jennifer B and Simeone, Diane M and Zogopoulos, George and Brand, Randall E and Graff, John J and Earl, Julie and PRECEDE Consortium, PRECEDE Consortium},
  title = {Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {8},
  pages = {1873--1883},
  doi = {10.1002/ijc.70592}
}
Kostenlos starten →